# US 2003/0232805 A1 · Prevention and treatment of functional somatic disorders, including stress-related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0232805 A1
- Document ID: US20030232805A1
- Status: Published application
- Kind: A1
- Application number: 10/424,212
- Filed: 2003-04-24
- Published: 2003-12-18
- Earliest claimed: 2002-04-24
- Assignees: Cypress Bioscience, Inc.
- Inventors: Jay D. Kranzler; Srinivas G. Rao
- Web page: https://patentgrep.com/patent/US20030232805A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/38: having sulfur as a ring hetero atom
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 13/10: of the bladder
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for the prevention or treatment of stress-related disorders by administering a therapeutically effective amount of a dual serotonin/norepinephrine reuptake inhibitor to an individual under stress are described. A triple monoamine reuptake inhibitor for serotonin/noradrenaline/dopamine may also be administered to an individual at risk for a stress-related disorder. In a preferred embodiment the compound is milnacipran and is prophylactically administered at an effective amount to delay or prevent stress-related disorders in an individual at risk.

## Claims

### Claim 1

A method for prevention or treatment of stress-related disorders comprising administering to a patient at risk of developing a stress-related disorder, or having a stress-related disorder, an effective amount of a pharmaceutical compound selected from the group consisting of dual reuptake inhibitor (DRI) pharmaceutical compounds, and a triple reuptake inhibitor (TRI) pharmaceutical compounds, to delay or prevent the onset of the stress-related disorder or to alleviate symptoms of the stress-related disorder.

### Claim 2 (depends on 1)

The method of claim 1 wherein the DRI is an SNRI compound.

### Claim 3 (depends on 1)

The method of claim 1 wherein the DRI is an NSRI compound.

### Claim 4 (depends on 1)

The method of claim 1 wherein the DRI compound has NMDA antagonist activity.

### Claim 5 (depends on 3)

The method of claim 3 wherein the NSRI compound also has NMDA antagonist activity.

### Claim 6 (depends on 2)

The method of claim 2 wherein the SNRI compound is selected from the group consisting of duloxetine and venlafaxine.

### Claim 7 (depends on 5)

The method of claim 5 wherein the NSRI compound is milnacipran.

### Claim 8 (depends on 1)

The method of claim 1 wherein the TRI compound has NMDA antagonist activity.

### Claim 9 (depends on 1)

The method of claim 1 wherein the TRI is sibutramine.

### Claim 10 (depends on 1)

The method of claim 1 wherein the stress-related disorder is a functional somatic disorder.

### Claim 11 (depends on 1)

The method of claim 1 wherein the FSD or symptom of FSD is selected from the group consisting of MTH, IBS, AFP, PMDD, TMD, NCCP, MCS, LBP, IC, and CPP.

### Claim 12 (depends on 1)

The method of claim 1, wherein the pharmaceutical compound is adjunctively administered with an agent selected from the group consisting of neurontin, pregabalin, pramipexole, L-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, a tricyclic antidepressant, codeine, carbamazepine, sibutramine, amphetamine, valium, and trazodone.

### Claim 13 (depends on 1)

The method of claim 1 wherein the stress-related disorder is selected from the group consisting of anxiety, post traumatic stress disorder, and Gulf War Syndrome.

### Claim 14 (depends on 7)

The method of claim 7, wherein the amount administered is from about 25 mg to about 400 mg per day.

### Claim 15 (depends on 14)

The method of claim 14 wherein the amount administered is from approximately 100 mg per day to 250 mg per day.

### Claim 16 (depends on 7)

The method according to claim 7, wherein the milnacipran is formulated in a sustained release dosage formulation.

### Claim 17 (depends on 1)

The method of claim 1 wherein the pharmaceutical compound is administered until the stressor is relieved.

### Claim 18 (depends on 1)

The method of claim 1 wherein the pharmaceutical compound is administered for 2 weeks.

### Claim 19 (depends on 1)

The method of claim 1 wherein the pharmaceutical compound is administered for 6 months.

### Claim 20 (depends on 1)

The method of claim 1 wherein the pharmaceutical compound is administered for one or more years.

### Claim 21 (depends on 1)

The method of claim 1 wherein the compound is administered before occurrence of a stressful event.

### Claim 22 (depends on 1)

The method of claim 1 wherein the compound is administered during the occurrence of a stressful event.

### Claim 23 (depends on 1)

The method of claim 1 wherein the compound is administered shortly after the occurrence of a stressful event.

### Claim 24 (depends on 1)

The method of claim 1 for preventing or treating FSD by pharmaceutically correcting dysfunction in two or more pathways selected from the list consisting of neurotransmitter dysfunction, HPA dysfunction and neuroendocrine dysfunction.

### Claim 25 (depends on 1)

The method of claim 1 for preventing or treating FSD in a person having one or more symptoms of FSD, the method comprising administering to the person one or more SNRI pharmaceutical compounds that treat two or more symptoms selected from the list consisting of: chronic pain, neurotransmitter changes, neuroendocrine changes, sleep disturbances, and fatigue

### Claim 26 (depends on 1)

The method of claim 1 for preventing or treating FSD in a person having one or more symptoms of FSD, the method comprising simultaneously treating at least one somatic symptom and one CNS symptom of the FSD.
